Colestimide Lowers Plasma Glucose Levels and Increases Plasma Glucagon-like Peptide-1 (7-36) Levels in Patients with Type 2 Diabetes Mellitus Complicated by Hypercholesterolemia

Tatsuya Suzuki; Kenzo Oba; Yoshimasa Igari; Noriaki Matsumura; Kentaro Watanabe; Shoko Futami-Suda; Hiroko Yasuoka; Motoshi Ouchi; Kazunari Suzuki; Yoshiaki Kigawa; Hiroshi Nakano

doi:10.1272/jnms.74.338

Originals

Colestimide Lowers Plasma Glucose Levels and Increases Plasma Glucagon-like Peptide-1 (7-36) Levels in Patients with Type 2 Diabetes Mellitus Complicated by Hypercholesterolemia

Tatsuya Suzuki, Kenzo Oba, Yoshimasa Igari, Noriaki Matsumura, Kentaro Watanabe, Shoko Futami-Suda, Hiroko Yasuoka, Motoshi Ouchi, Kazunari Suzuki, Yoshiaki Kigawa, Hiroshi Nakano

Author information

Tatsuya Suzuki
Department of Functional Pathophysiology for Human Organs, Graduate School of Medicine, Nippon Medical School
Kenzo Oba
Department of Functional Pathophysiology for Human Organs, Graduate School of Medicine, Nippon Medical School
Yoshimasa Igari
Department of Functional Pathophysiology for Human Organs, Graduate School of Medicine, Nippon Medical School
Noriaki Matsumura
Department of Functional Pathophysiology for Human Organs, Graduate School of Medicine, Nippon Medical School
Kentaro Watanabe
Department of Functional Pathophysiology for Human Organs, Graduate School of Medicine, Nippon Medical School
Shoko Futami-Suda
Department of Functional Pathophysiology for Human Organs, Graduate School of Medicine, Nippon Medical School
Hiroko Yasuoka
Department of Functional Pathophysiology for Human Organs, Graduate School of Medicine, Nippon Medical School
Motoshi Ouchi
Department of Functional Pathophysiology for Human Organs, Graduate School of Medicine, Nippon Medical School
Kazunari Suzuki
Department of Functional Pathophysiology for Human Organs, Graduate School of Medicine, Nippon Medical School
Yoshiaki Kigawa
Hanno Geriatric Hospital, Saitama
Hiroshi Nakano
Department of Functional Pathophysiology for Human Organs, Graduate School of Medicine, Nippon Medical School

Keywords: colestimide, glucagon-like peptide-1, glycemic control, type 2 diabetes mellitus

JOURNAL FREE ACCESS

2007 Volume 74 Issue 5 Pages 338-343

DOI https://doi.org/10.1272/jnms.74.338

Details

Abstract

Background: Colestimide has been reported to lower blood glucose levels in patients with type 2 diabetes complicated by hypercholesterolemia.
Aim: To examine the mechanism by which colestimide decreases plasma glucose levels in the above patients.
Methods: A total of 16 inpatients with type 2 diabetes complicated by hypercholesterolemia received colestimide for 1 week after their plasma glucose levels stabilized. We measured plasma glucose, serum immunoreactive insulin (IRI), serum lipid, plasma glucagon, and plasma glucagon-like peptide-1 (GLP-1) levels. These variables at baseline and 1 week of colestimide administration were compared.
Results: Preprandial plasma glucose levels (baseline: 132 ± 33 mg/dL vs. completion: 118 ± 43 mg/dL, P=0.073) tended to decrease after colestimide administration, while 1-hr postprandial plasma glucose levels (baseline: 208 ± 49 mg/dL vs. completion: 166 ± 30 mg/dL, P<0.001) and 2-hr postprandial plasma glucose levels (baseline: 209 ± 56 mg/dL vs. completion: 178 ± 39 mg/dL, P=0.015) decreased significantly at 1 week of colestimide administration. The 2-hr postprandial plasma GLP-1 level was significantly (P=0.015) higher at 1 week of colestimide administration as compared with the baseline level, while there were no significant changes in preprandial and 1-hr postprandial plasma GLP-1 levels.
Conclusions: The GLP-1-increasing activity of colestimide may explain, at least in part, the mechanism of its blood glucose-lowering activity in patients with type 2 diabetes complicated by hypercholesterolemia.

Corresponding author

Register with J-STAGE for free!